As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
Content to be used in accordance with local CPO guidelines
A phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy (VAYHIT3)
Charlotte Bradbury*, Tugrul Elverdi, Karolin Trautmann, Mathias Rummel, Alessandra Borchiellini, Huyen Tran, Jae-Ho Yoon, Nichola Cooper, Guillaume Moulis, Thomas Stauch, Sebastian Grosicki, Fabienne Le Gac, Alex Allepuz, Patrick Urban, Renxin Lin, Tomás José González-López, David J Kuter
Oral presentation #S312
Amber Hall 3+4 | Sunday, June 15, 2025 | 11:30 – 11:45 CEST
Efficacy of ianalumab in a mouse model of autoimmune hemolytic anemia (AIHA)
Karina Yazdanbakhsh*, Weili Bao, Shan Su, Yunfeng Liu, Marc Bigaud, Elissa Furutani, Tatjana Uffelmann, Pascal Edrich, Barbara Nüsslein-Hildesheim, Isabelle Isnardi, Christoph Burkhart
Poster presentation #PS2257
Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
Ianalumab‘s dual mechanism of action: Targeting B cells through enhanced B-cell depletion and blockade of B cell-activating factor receptor signaling
Catherine Wioland, Corinne Vedrine, Caroline Walter, Fanny Marque, Thomas Dannequin, Johan Rebetz, Genvieve Marcoux, Marc Bigaud, Elissa Furutani, Tatjana Uffelmann, Pascal Edrich, Sabina Pfister, Barbara Nüsslein-Hildesheim, Cindy Schmid, Elena Degl’innocenti, Gautier Robert, David Schubert, Catriona Paape, Christoph Burkhart*, John W Semple, Isabelle Isnardi
Poster presentation #PS2237
Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
